The ability of known COX-2 selective inhibitor celecoxib (1), 5-azido-pyraozles (5 and 14) and new triazole products (7–12, 16–25, 28, 29, 32, and 33) to inhibit ovine COX-1 and recombinant human COX-2 was determined using a COX inhibitor assay (Cayman Chemical, Ann Arbor, USA; item number: 700100) following the manufacturer’s protocol. Each compound was assayed in concentration range of 10−9 M to 10−3 M, in triplicate. PRISM5 software was used to calculate IC50 values. In addition to celecoxib, both Dup-697 (potent COX-2 inhibitor) and SC-560 (potent COX-1 inhibitor) were used as internal controls during screening test compounds.
Free full text: Click here